A Study Regarding Tissue Response During and After Treatment for Anal Cancer

Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how anal cancer responds to treatment. Researchers want to learn more about the tumor's environment, how the cancer interacts with immune cells, and how certain genes and proteins behave in the tumor and nearby tissues. By studying these factors, the goal is to improve treatment strategies for patients with anal cancer.

To participate in this study, individuals must be between 65 and 74 years old and have either newly diagnosed or recurrent anal cancer. Unfortunately, those who do not have a diagnosis of anal cancer or cannot undergo biopsies and blood tests will not be eligible. Participants can expect to provide samples of their tumor and blood, which will help researchers gather important information about the disease and its treatment. This study is currently looking for volunteers, and everyone's contribution could help advance our understanding of anal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed or recurrent anal cancer
• Exclusion Criteria:
• • No diagnosis of anal cancer, contraindication to biopsies and blood samples